Meeting
2023 ASCO Genitourinary Cancers Symposium
Impact of pre-existing anemia and/or packed red blood cell transfusion prior to Radium-223 administration on oncologic outcomes.
Authors
Michael Pierro
Medical College of Wisconsin, Milwaukee, WI
Michael Pierro , Ariel Ann Nelson , John Xie , Albert Jang , Kathryn A. Bylow , Pedro C. Barata , Colleen Anne Lawton , Deepak Kilari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 67)
DOI
10.1200/JCO.2023.41.6_suppl.67
Abstract #
67
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.
First Author: Amer Methqal Zeidan
Poster
2024 ASCO Annual Meeting
Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.
First Author: Stephen Oh
Poster
2024 ASCO Annual Meeting
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.
First Author: Pankit Vachhani
Poster
2023 ASCO Annual Meeting
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
First Author: Aaron Thomas Gerds